Our Mission

Our mission is to organize educational programs that inform physicians about the latest medical and scientific advances in their field, help increase their knowledge and skills, and improve the outcomes for their patients.  The programs will especially focus on the evolving  key areas in diagnostics  and therapeutics that concern Academic and practicing neurologists including new  clinical criteria governing certain neurological diseases, updated state of the art neuro-therapeutics and pathogenesis, neuro-rehabiliation, neurology-imaging, updates on the most recent consensus criteria on disease classification, diagnosis, management and future perspectives on various rapidly evolving therapeutics or drugs for difficult to treat neurological disorders. Our faculties consist of renowned experts in the field, who will ensure that the information provided is accurate, evidence-based, supported by the medical literature and free of any commercial bias.

Recognized and experienced academic neurologists at the professor level will be providing guidance to the Managing Director team

Our Team

Elizabeth Williams

Managing Director

Bruce Blake

Managing Director


Before founding Neuro-EDU in 2019, their third neurology concentrated startup, Mrs. Williams and Mr. Blake, were co-founders and the executive leadership at the two neurology-focused healthcare companies.

The first company, American Disease Management (ADIMA), provided specialty compounded pharmaceuticals centered on neurological diseases. ADIMA was sold to Bioscrip, NASDAQ: BIOS Prescription Benefits Management (PBM) company, in August 2000. In August 2019 Bioscrip merged with Option Care Health NASDAQ: OPCH.

The second organization, Therapath Neuropathology, located in mid-town Manhattan, was focused exclusively on Neuropathology, specifically muscle, nerve, brain, and epidermal nerve testing. The company was sold to Avista Capital Partners, a private equity healthcare firm, and one of their portfolio companies, Inform Diagnostics, in April 2018. In April 2022, Fulgent Genetics NASDAQ: FLGT acquired Therapath and Inform Diagnostics.